Thyroid cancer

This phase 2 trial tests a combination of the immunotherapy drug PDR001 with either trametinib or dabrafenib in 19 patients with thyroid cancer that no longer responds to radioiodine treatment. The goal is to see if the combination can shrink tumors. The study is active but no lo…

This study tests the drug vemurafenib in 24 people with advanced papillary thyroid cancer that has a BRAF gene mutation. The drug aims to block this mutation to shrink tumors before surgery. Researchers will measure changes in tumor size and biomarkers in blood and tissue over 56…

This Phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in 12 people with advanced anaplastic thyroid cancer, a rare and fast-growing cancer with no standard cure. Participants receive the drug every three weeks to see if tumors shrink or stop growing. The study …

This early-phase trial tests whether giving advanced thyroid cancer patients a personalized mix of already-approved drugs, chosen based on their tumor's genetic profile, is feasible and safe. Ten patients with no other treatment options will receive individualized drug combinatio…

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This trial is testing whether adding the immunotherapy drug durvalumab to standard radioiodine treatment can help people with recurrent or metastatic thyroid cancer. The study includes patients whose tumors still absorb iodine, as seen on scans. The goal is to see if the combinat…

This phase 2 trial tests whether combining lenvatinib (a targeted drug that blocks cancer growth) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can improve outcomes for people with advanced anaplastic thyroid cancer that cannot be surgically rem…

This trial is testing whether a precise, high-dose form of radiation called stereotactic body radiotherapy (SBRT) can control distant metastases in people with stage IV thyroid cancer. The study enrolls patients with up to five metastatic lesions who have already tried systemic t…

This early study tests if a laser can safely destroy small thyroid cancers (papillary thyroid microcarcinoma) without removing the thyroid. Ten adults with small tumors will receive laser treatment, then have their thyroid removed 6 months later to check if the cancer is fully go…

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with anaplastic or poorly differentiated thyroid cancer live longer. About 50 patients with advanced or inoperable cancer are receiving different drug combinations…

This phase 2 trial tests whether combining two oral drugs—sorafenib and everolimus—can shrink tumors or slow disease in people with advanced thyroid cancer that cannot be removed by surgery. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps…

This phase 1 study tests whether adding a highly targeted, high-dose radiation boost (stereotactic body radiotherapy, or SBRT) to standard radiation and chemotherapy can safely treat head and neck cancer that has come back or spread. The trial includes two groups: patients whose …

This study tests whether adding the immunotherapy drug cemiplimab to the usual combination of dabrafenib and trametinib can shrink tumors in people with a rare and aggressive form of thyroid cancer called anaplastic thyroid cancer. Participants have a specific genetic mutation (B…

This phase 2 trial tests whether giving selpercatinib before standard surgery can shrink tumors in people with RET-altered thyroid cancer. About 30 participants with advanced or recurrent disease will receive the drug and then undergo surgery. The goal is to see if the drug impro…

This early-phase trial tested a combination of two targeted drugs, dabrafenib and lapatinib, in 23 people with advanced thyroid cancer that had a specific BRAF mutation and could not be removed by surgery. The main goal was to find the safest dose of lapatinib when given with dab…

This study looks at whether low-risk thyroid cancer patients need radioactive iodine treatment after having their thyroid removed. About 504 participants are randomly assigned to receive either a standard dose of radio-iodine or no radio-iodine at all. The goal is to see if skipp…

This phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug docetaxel can shrink or control advanced thyroid and salivary gland cancers that are not responding to standard treatments. About 46 participants will receiv…

This study looks at whether removing only the thyroid gland works as well as also removing nearby lymph nodes in people with low-risk thyroid cancer. About 352 patients with small to medium-sized tumors will be randomly assigned to one of the two surgeries. The goal is to see if …

This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…

Researchers are testing a technique called Raman spectroscopy to see if it can accurately identify thyroid cancer in tissue samples. The study involves patients who are already having a routine thyroid biopsy for suspected cancer. After the biopsy, the removed tissue is examined …

This study is testing a new way to analyze thyroid nodules that look suspicious but not clearly cancerous. Researchers are checking if a set of microRNA molecules can better predict which nodules are actually cancer. The goal is to help patients avoid unnecessary surgery. The stu…

This study tests a new imaging tracer called 18F-TFB to see if it can show how well thyroid cancer cells take up radioactive iodine. The goal is to get results faster than current methods and without affecting later treatment. About 5 adults with thyroid cancer will receive the t…

This study is testing a new imaging method called Cerenkov luminescence imaging, which uses light naturally given off by certain radioactive substances used in standard cancer scans. Researchers want to see if this technique can take clear pictures of thyroid cancer and tumors th…

This study looks at whether proteins found in urine can help doctors diagnose follicular thyroid cancer before surgery. Currently, this type of thyroid cancer can only be confirmed after removing the thyroid. Researchers will collect urine samples from 50 patients with thyroid no…

This study is testing an artificial intelligence (AI) tool that helps doctors read thyroid ultrasound images. Researchers want to see if the AI can make diagnoses more consistent and faster than traditional methods. About 2,000 adults from 16 hospitals in China will take part. Th…

Researchers at the University of Aarhus are studying whether people with a single thyroid cancer smaller than 2 cm can safely delay surgery and instead have the tumor monitored with ultrasound for five years. The study enrolls 90 adults aged 30 and older whose biopsy shows cancer…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This study aims to develop a survey that measures what patients expect before undergoing surgery for thyroid cancer. Researchers will interview patients before and after their operation to identify common themes and concerns. The goal is to create a tool that helps doctors better…

This study tests whether an artificial intelligence (AI) tool can help medical students and doctors more accurately determine the stage and risk level of thyroid cancer. About 70 participants will review patient cases, some with AI help and some without. The goal is to see if the…

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study follows 107 thyroid cancer patients who need radioiodine therapy or scans. It compares two ways to prepare: a Thyrogen injection or stopping Eltroxin medication. The goal is to see how these methods affect depression, metabolism, and other health markers. No new treatm…

This study is testing whether substances found in urine can help doctors monitor thyroid cancer after treatment. Researchers are collecting urine samples from 103 people who had their thyroid removed and/or radioactive iodine therapy. They are looking for specific proteins in the…

This study looks at women with thyroid cancer who get a radioactive iodine whole body scan after thyroid removal. Researchers want to see if the way patients are prepared for the scan—either by stopping thyroid hormone or using a special injection—affects how much iodine is taken…

This study follows 200 adults with low-risk papillary thyroid cancer to see how many choose active surveillance (close monitoring) instead of surgery, and why. Researchers also track decision regret and quality of life over time. The goal is to understand if offering monitoring a…

This study aimed to see if thyroid surgery changes the thickness of the carotid artery, which is a sign of heart disease risk. It planned to measure artery thickness before and after surgery in adults with various thyroid conditions. However, the study was withdrawn before enroll…